Archives
-
2-Hydroxypropyl-β-cyclodextrin Protocol Guide
2026-10-01
2-Hydroxypropyl-β-cyclodextrin is a water-soluble cyclic oligosaccharide for improving the aqueous handling of poorly soluble hydrophobic compounds, particularly molecules containing aromatic or phenyl groups. In the absence of directly matched paper evidence, it should be used as a research solubilizer or drug formulation excipient within a qualified inclusion-complex workflow, not as evidence of bioavailability, efficacy, safety, or clinical suitability.
-
Multiplexed CRISPR–Cas for Genome Engineering
2026-10-01
The 2025 review by Cheng, Jeong, and Cho explains how multiplexed CRISPR–Cas systems can simultaneously disrupt genes, generate structural variants, reprogram gene expression, and induce selective cellular stress. Its central practical message is that multiplexing expands genome engineering beyond single-gene knockout, but requires careful control of guide design, DNA-damage burden, repair outcomes, and assay interpretation.
-
EZ Cap™ Human PTEN mRNA Workflow Guide
2026-09-30
Build reproducible PTEN restoration experiments with Cap 1 and poly(A)-tailed mRNA, from cell transfection to nanoparticle screening. This guide connects cancer mechanism studies with emerging tissue-targeted delivery strategies, including blood–brain-barrier models.
-
DiscoveryProbe Natural Product Library Plus in HTS
2026-09-30
Explore how the DiscoveryProbe Natural Product Library Plus can extend enzyme-to-phenotype screening for parasite drug discovery. This article translates recent CpAdhE findings into a practical, orthogonal workflow for natural product screening, target validation, and mechanism-aware hit triage.
-
CGP 55845 Hydrochloride: Assay Logic for GABAB
2026-09-29
CGP 55845 hydrochloride enables selective GABAB receptor antagonism, but its greatest value emerges when receptor pharmacology is integrated with astrocyte and presynaptic readouts. This article develops an assay-design framework grounded in recent dentate gyrus research and distinguishes receptor blockade from GAT-3-dependent glial signaling.
-
SMYD2 Inhibition in Cisplatin-Induced Renal Fibrosis
2026-09-29
The reference study identifies SMYD2 as a pharmacologically actionable regulator of cisplatin-induced renal fibrosis and inflammation. Using AZ505 and LLY507 in an in vivo disease model, together with tubular epithelial cell experiments, the authors connect SMYD2 inhibition with reduced epithelial–mesenchymal transition, inflammatory signaling, and Smad3/STAT3 activity.
-
Pregnenolone Carbonitrile: Assay Design Guide
2026-09-28
Pregnenolone Carbonitrile is a versatile rodent PXR agonist for connecting CYP3A regulation, xenobiotic metabolism, fibrosis biology, and water homeostasis. This guide translates recent AVP findings into practical assay design and interpretation decisions.
-
Bivalent mRNA–LNP Vaccine Protects Chickens from H5/H7
2026-09-28
Wei and colleagues evaluated a nucleoside-modified, bivalent mRNA–LNP vaccine encoding H5N1 and H7N9 hemagglutinins in SPF chickens. The vaccine induced dose-dependent antibody responses, and the 50- and 80-μg groups showed complete protection in the reported lethal challenge experiments, alongside reduced viral replication and shedding.
-
MK-571: Dual-Target Clues in Macrophage Resilience
2026-09-27
MK-571 (L-660,711) is known for blocking cysteinyl leukotriene signaling, but its MRP1 activity creates a second experimental lens. This article examines how a macrophage chemotherapy study changes assay interpretation—and what it does not yet prove.
-
HyperScribe Co-transcription mRNA Synthesis Kit Plus
2026-09-26
Build translation-oriented, ARCA-capped mRNA with a template-encoded poly(A) tail using a practical in vitro transcription workflow. See how the HyperScribe kit can support vaccine-design assays, including GPC3-HSP70 nanovaccine research, while keeping transcript quality checks distinct from downstream delivery and efficacy testing.
-
tFUS Limits NLRP3 Inflammation After Ischemic Stroke
2026-09-25
A rat ischemic-stroke study links low-intensity transcranial focused ultrasound stimulation (tFUS) to reduced NLRP3 inflammasome activation and improved neurological outcomes. Its mechanistic experiments identify the Nespas/miR-383-3p/SHP2 axis as a candidate mediator, while indicating that SHP2 inhibition may worsen rather than relieve inflammation in this model.
-
PP 2 (AG 1879): Reading Src Biology in Context
2026-09-25
A vascular study puts PP 2 (AG 1879) in useful mechanistic perspective: Src inhibition can alter contraction without mediating the procontractile effect of NADPH oxidase-derived ROS. Learn how translational teams can use this probe to test pathway dependence while avoiding overinterpretation across biological systems.
-
Pregnenolone Carbonitrile in the Gut–Liver Axis
2026-09-24
Pregnenolone Carbonitrile is more than a tool for studying CYP3A induction: new mouse research connects PXR activation with microbiota-dependent YAP signaling during sepsis-associated liver injury. Learn what this finding means for model selection, controls, and interpreting hepatic protection.
-
mCherry mRNA for LNP Delivery Assays
2026-09-24
Use red fluorescent protein mRNA to test whether a delivery workflow produces functional protein expression—not merely whether particles contact cells. This practical guide pairs EZ Cap™ mCherry mRNA with an LNP-focused fibroblast use case, while separating reporter readouts from the evidence needed to confirm gene editing.
-
MK-5108 (VX-689) Aurora-A Research Workflows
2026-09-23
Use MK-5108 (VX-689) to connect Aurora-A target engagement with cell-cycle and tumor-growth readouts, while keeping biochemical potency separate from cellular dose selection. This workflow adapts retinoblastoma findings into practical experiments and highlights controls for selectivity, solvent effects, and assay interpretation.